Seeking Alpha

The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing...

The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing up to start buying again. Five of the largest U.S. drug makers have spent the last several years building up their cash positions in anticipation of expiring patents. Now, with nearly $70B in cash equivalents at their disposal, all eyes are on JPMorgan’s annual health-care conference in San Francisco, where the big drug makers will likely be on the hunt for assets to fill revenue holes left by expired patents.
Comments (2)
  • RSI Raistlin
    , contributor
    Comments (400) | Send Message
     
    vicl, clsn maybe?
    7 Jan 2013, 09:48 PM Reply Like
  • chopchop0
    , contributor
    Comments (3148) | Send Message
     
    This is why biotech has been an awesome sector to be in the last couple years. It's been hard to pick all the winners so I've stuck with the ETFs, IBB and XBI. despite being ETFs, they've done quite well in the last 1-2 years
    7 Jan 2013, 10:20 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|